Practical considerations for cangrelor use in patients with acute coronary syndromes

Sergio Leonardi; Deepak L. Bhatt

doi:10.1177/2048872617707960

Practical considerations for cangrelor use in patients with acute coronary syndromes

Sergio Leonardi, Deepak L. Bhatt

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Cangrelor, the first and currently only available intravenous P2Y12 receptor antagonist, has been approved and is now being used in patients with coronary artery disease requiring percutaneous coronary intervention. The rationale for cangrelor use is most robust in patients requiring an immediate, profound, and predictable level of P2Y12 inhibition - especially in patients with acute coronary syndromes. Herein we summarize the drug development program and reflect on practical considerations for clinicians on cangrelor use in the acute setting surrounding percutaneous coronary intervention, including selection of patients, concomitant administration of glycoprotein IIb/IIIa inhibitors and transition strategies from intravenous to oral P2Y12 receptor antagonists.

Original language	English
Pages (from-to)	39-44
Number of pages	6
Journal	European heart journal. Acute cardiovascular care
Volume	8
Issue number	1
DOIs	https://doi.org/10.1177/2048872617707960
Publication status	Published - Feb 1 2019

Keywords

Acute coronary syndromes
cangrelor
percutaneous coronary intervention

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1177/2048872617707960

Fingerprint Dive into the research topics of 'Practical considerations for cangrelor use in patients with acute coronary syndromes'. Together they form a unique fingerprint.

Cite this

@article{221b5b889f4d46b7b890ed69711e1608,

title = "Practical considerations for cangrelor use in patients with acute coronary syndromes",

abstract = "Cangrelor, the first and currently only available intravenous P2Y12 receptor antagonist, has been approved and is now being used in patients with coronary artery disease requiring percutaneous coronary intervention. The rationale for cangrelor use is most robust in patients requiring an immediate, profound, and predictable level of P2Y12 inhibition - especially in patients with acute coronary syndromes. Herein we summarize the drug development program and reflect on practical considerations for clinicians on cangrelor use in the acute setting surrounding percutaneous coronary intervention, including selection of patients, concomitant administration of glycoprotein IIb/IIIa inhibitors and transition strategies from intravenous to oral P2Y12 receptor antagonists.",

keywords = "Acute coronary syndromes, cangrelor, percutaneous coronary intervention",

author = "Sergio Leonardi and Bhatt, {Deepak L.}",

year = "2019",

month = feb,

day = "1",

doi = "10.1177/2048872617707960",

language = "English",

volume = "8",

pages = "39--44",

journal = "European Heart Journal: Acute Cardiovascular Care",

issn = "2048-8726",

publisher = "Sage Publications",

number = "1",

}

TY - JOUR

T1 - Practical considerations for cangrelor use in patients with acute coronary syndromes

AU - Leonardi, Sergio

AU - Bhatt, Deepak L.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Cangrelor, the first and currently only available intravenous P2Y12 receptor antagonist, has been approved and is now being used in patients with coronary artery disease requiring percutaneous coronary intervention. The rationale for cangrelor use is most robust in patients requiring an immediate, profound, and predictable level of P2Y12 inhibition - especially in patients with acute coronary syndromes. Herein we summarize the drug development program and reflect on practical considerations for clinicians on cangrelor use in the acute setting surrounding percutaneous coronary intervention, including selection of patients, concomitant administration of glycoprotein IIb/IIIa inhibitors and transition strategies from intravenous to oral P2Y12 receptor antagonists.

AB - Cangrelor, the first and currently only available intravenous P2Y12 receptor antagonist, has been approved and is now being used in patients with coronary artery disease requiring percutaneous coronary intervention. The rationale for cangrelor use is most robust in patients requiring an immediate, profound, and predictable level of P2Y12 inhibition - especially in patients with acute coronary syndromes. Herein we summarize the drug development program and reflect on practical considerations for clinicians on cangrelor use in the acute setting surrounding percutaneous coronary intervention, including selection of patients, concomitant administration of glycoprotein IIb/IIIa inhibitors and transition strategies from intravenous to oral P2Y12 receptor antagonists.

KW - Acute coronary syndromes

KW - cangrelor

KW - percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=85061286862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061286862&partnerID=8YFLogxK

U2 - 10.1177/2048872617707960

DO - 10.1177/2048872617707960

M3 - Article

C2 - 28574274

AN - SCOPUS:85061286862

VL - 8

SP - 39

EP - 44

JO - European Heart Journal: Acute Cardiovascular Care

JF - European Heart Journal: Acute Cardiovascular Care

SN - 2048-8726

IS - 1

ER -